American trypanosomiasis, or Chagas' disease, is caused by a protozoan, Trypanosoma cruzi. It is endemic in Latin America where it represents a major public health problem. Chagas' disease also occurs in non-endemic areas where it can be acquired by blood transfusion, congenital transmission and organ transplantation. The disease can be fatal in immunosuppressed patients. 1 We report a case of reactivation of Chagas' disease (acute form) in a patient who underwent cord blood transplantation in a non-endemic European country.
A 25-year-old male with high-risk acute myeloid leukemia was sent to our hospital in May 2005 for an unrelated cord blood transplant.
Pretransplant evaluation revealed a mild pancytopenia, lactate dehydrogenase 550 U/l and lupus anticoagulant. Electrocardiogram revealed abnormal Q waves and diffuse ST-T changes, left ventricular ejection was normal and myocardial scintigraphy showed perfusion defects in the apical and posterior-inferior segments. Brain natriuretic peptide was elevated. Cardiac dysfunction was attributed to lupus anticoagulant or anthracycline toxicity.
After a conditioning regimen with fractionated total body irradiation (1000 cGy in five doses), fludarabine (30 mg/m 2 /day Â 4 days), cyclophosphamide (60 mg/kg/ day Â 2 days) and anti-thymocyte globulin (lymphoglobuline 30 mg/kg Â 1 days), 2.28 Â 10 7 /kg nucleated cells from a cord blood unit were infused. On the same day, 2.86 Â 10 6 /kg CD133-positive cells from his haploidentical sibling were also infused, according to a local protocol. 2 Graft-versus-host disease prophylaxis was with cyclosporine A and prednisone.
On day þ 10 the patient achieved an absolute neutrophil count 40.5 Â 10 9 /l. On day þ 11 he developed fever, and empirical antimicrobial therapy was started. Results of bacteriological cultures of blood and urine were negative. CMV PCR, herpesvirus PCR, toxoplasma, polyomavirus and galactomannan were negative. Bone marrow aspiration showed hypocellularity and trilinear engraftment. On day þ 20, the fever persisted and the patient developed neuropsychiatric symptoms. Computed tomographic scan, magnetic resonance (MR) and cerebrospinal fluid analysis were normal.
On day þ 35 a viral culture (shell vial), obtained on day þ 20, revealed a growth of trypomastigotes of T. cruzi. On the same day, peripheral blood and bone marrow smears also revealed T. cruzi forms. Treatment with benznidazole (10 mg/kg/day p.o.) was started. However, 2 days later, the patient died because of multiorgan failure.
Autopsy revealed disseminated infection, with myocarditis and encephalitis caused by T. cruzi.
Our patient had never visited an endemic country and in this case the mode of transmission could be documented. Serological and polymerase chain reaction analysis of serial samples obtained before the transplant showed seroconversion and PCR positivity in February 2005 and an infected blood donor was identified retrospectively.
Immunosuppression associated with cord blood transplantation was responsible for the fatal outcome in this case. Chagas' disease is not endemic to European countries and diagnosis is difficult. Infected blood products used for transfusion are the most likely mechanism of transmission. It is estimated that approximately 10-20% of blood from chronically infected donors is infective. This disease can affect people in Europe owing to migration from endemic areas, mainly Latin America. Several serologic assays and PCR have been developed but the available screening tests are imperfect.
The cardiac abnormalities and ECG findings detected before conditioning in the patient could be attributed to Chagas' disease.
Several cases of acute Chagas' disease following solid organ and bone marrow transplantation has been described. 3, 4 Recently, the efficacy of pre-emptive therapy has been evaluated in hemopoietic transplant recipients.
